Treatment effect modifiers of virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: an exploratory moderator analysis of clinical and demographic characteristics in the FaceYourFears trial.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Treatment effect modifiers of virtual reality-based versus standard cognitive behavioral therapy for paranoia in schizophrenia spectrum disorders: an exploratory moderator analysis of clinical and demographic characteristics in the FaceYourFears trial.
Συγγραφείς:	Christensen MJ; Department of Psychiatry, https://ror.org/02jk5qe80Aalborg University Hospital, Aalborg, North Denmark Region, Denmark.; Department of Clinical Medicine, Aalborg University, Denmark., Vernal DL; Department of Psychiatry, https://ror.org/02jk5qe80Aalborg University Hospital, Aalborg, North Denmark Region, Denmark.; Department of Clinical Medicine, Aalborg University, Denmark., Jeppesen UN; Department of Psychology, https://ror.org/035b05819University of Copenhagen, Denmark.; VIRTU Research Group, Mental Health Center Copenhagen, https://ror.org/035b05819Copenhagen University Hospital - Mental Health Services CPH, Denmark., Hjorthøj C; Department of Public Health, https://ror.org/035b05819University of Copenhagen, Denmark.; https://ror.org/035b05819Copenhagen Research Centre for Mental Health (CORE), Capital Region, Denmark., Mainz J; Department of Psychiatry, https://ror.org/02jk5qe80Aalborg University Hospital, Aalborg, North Denmark Region, Denmark.; Department of Clinical Medicine, Aalborg University, Denmark.; Department of Health Economics, https://ror.org/03yrrjy16University of Southern Denmark, Odense, Denmark., Pinkham A; School of Behavioral and Brain Sciences, https://ror.org/049emcs32University of Texas at Dallas, USA., Austin S; Department of Psychology, https://ror.org/035b05819University of Copenhagen, Denmark.; Mental Health Services East, https://ror.org/035b05819Copenhagen University Hospital - Psychiatry Region Zealand, Roskilde, Denmark., Veling W; Centre of Psychiatry, University Medical Center Groningen, Faculty of Medical Sciences, https://ror.org/03cv38k47University of Groningen, Netherlands., Ward T; South London & Maudsley NHS Foundation Trust, London, UK.; Department of Psychology, Institute of Psychiatry, Psychology & Neuroscience, https://ror.org/0220mzb33King's College London, London, UK., Nordentoft M; https://ror.org/035b05819Copenhagen Research Centre for Mental Health (CORE), Capital Region, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, https://ror.org/035b05819University of Copenhagen, Denmark., Glenthøj LB; Department of Psychology, https://ror.org/035b05819University of Copenhagen, Denmark.; VIRTU Research Group, Mental Health Center Copenhagen, https://ror.org/035b05819Copenhagen University Hospital - Mental Health Services CPH, Denmark.
Πηγή:	Psychological medicine [Psychol Med] 2026 Apr 27; Vol. 56, pp. e117. Date of Electronic Publication: 2026 Apr 27.
Τύπος έκδοσης:	Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Cambridge University Press Country of Publication: England NLM ID: 1254142 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-8978 (Electronic) Linking ISSN: 00332917 NLM ISO Abbreviation: Psychol Med Subsets: MEDLINE
Imprint Name(s):	Publication: London : Cambridge University Press Original Publication: London, British Medical Assn.
Ιατρικοί όροι (MeSH):	Cognitive Behavioral Therapy/methods , Paranoid Disorders/therapy , Paranoid Disorders/etiology , Psychotic Disorders/therapy , Psychotic Disorders/complications , Schizophrenia/complications , Schizophrenia/therapy , Virtual Reality Exposure Therapy/methods, Adult ; Female ; Humans ; Male ; Middle Aged ; Delusions ; Treatment Effect Heterogeneity ; Treatment Outcome ; Virtual Reality
Περίληψη:	Background: This exploratory study examined baseline characteristics modifying treatment effects on paranoia in individuals diagnosed with schizophrenia spectrum disorders following a 10-session virtual reality-based cognitive behavioral therapy for psychosis (VR-CBTp) or standard CBTp. Methods: All participants in the FaceYourFears trial were included (n=254; CBTp n=128; VR-CBTp n=126). General linear and logistic regression models examined baseline variables associated with end-of-treatment paranoia. In covariate analyses, regression coefficients quantified associations across treatments. In moderation analyses, interaction terms (randomization x moderator) were tested, with corresponding regression coefficients estimated and assessed at the 25th (low), 50th (medium), and 75th (high) percentiles of continuous variables. Results: Across treatments, higher baseline avolition, safety behavior, delusion severity, and cognitive biases were associated with end-of-treatment paranoia. Moderation analyses revealed interactions for avolition, delusion severity, and negative other-beliefs. Although avolition and delusion severity were associated with poorer outcomes overall, individuals with high avolition and those with moderate-to-high delusion severity improved more in VR-CBTp than CBTp, whereas participants with lower delusion severity showed better outcomes in CBTp. No demographic (age, gender, education, and occupation) or other clinical characteristics (diagnosis, paranoia, social anxiety, depression, anhedonia, total negative symptoms, functioning, core beliefs, or interpersonal trauma) were significantly associated with outcome. Conclusions: This exploratory study generates hypotheses for future research, including VR-CBTp's potential to engage individuals with high avolition. Given the modest effects and largely nonsignificant findings, both CBTp and VR-CBTp appear suitable for a wide range of individuals with paranoia, highlighting the importance of considering patient preferences.
References:	Schizophr Bull. 2009 Sep;35(5):859-64. (PMID: 19571248) J Behav Ther Exp Psychiatry. 2023 Dec;81:101893. (PMID: 37453405) J Clin Epidemiol. 2006 Sep;59(9):920-5. (PMID: 16895814) Clin Psychol Sci. 2019 Jan;7(1):37-50. (PMID: 30713811) J Consult Clin Psychol. 2004 Aug;72(4):671-80. (PMID: 15301652) Psychol Med. 2025 Jul 07;55:e188. (PMID: 40619608) Clin Psychol Psychother. 2024 Jul-Aug;31(4):e3019. (PMID: 38940680) Expert Rev Neurother. 2025 May;25(5):579-590. (PMID: 40162797) Psychol Med. 2016 Dec;46(16):3339-3348. (PMID: 27619196) Front Psychiatry. 2020 May 05;11:402. (PMID: 32431633) Eur J Psychotraumatol. 2018 Sep 11;9(1):1512265. (PMID: 30220986) Psychol Med. 2006 Jun;36(6):749-59. (PMID: 16563204) JAMA Psychiatry. 2024 Oct 1;81(10):1039-1046. (PMID: 39110444) Schizophr Res. 2022 Dec;250:152-163. (PMID: 36417817) Early Interv Psychiatry. 2022 Dec;16(12):1278-1296. (PMID: 35396904) J Ment Health. 2020 Oct;29(5):513-523. (PMID: 30862219) Clin Psychol Rev. 2024 Nov;113:102471. (PMID: 39111125) Acta Psychiatr Scand. 2025 Mar;151(3):293-303. (PMID: 38853472) Behav Ther. 2016 Sep;47(5):755-772. (PMID: 27816086) NPJ Schizophr. 2021 Feb 26;7(1):16. (PMID: 33637748) Front Psychiatry. 2022 Aug 04;13:940124. (PMID: 35990079) Behav Cogn Psychother. 2011 Mar;39(2):129-38. (PMID: 21062528) Lancet Psychiatry. 2021 Mar;8(3):237-249. (PMID: 33485408) EClinicalMedicine. 2023 Nov 09;65:102291. (PMID: 38021372) EClinicalMedicine. 2024 Jan 05;67:102392. (PMID: 38274116) Schizophr Res. 2021 May;231:154-163. (PMID: 33866260) Schizophr Res. 2024 Feb;264:435-447. (PMID: 38245930) Schizophr Res. 2013 Mar;144(1-3):63-71. (PMID: 23332365) Behav Cogn Psychother. 2025 Sep;53(3):224-237. (PMID: 40859842) Front Integr Neurosci. 2022 Jan 24;15:726321. (PMID: 35140591) Psychol Med. 2024 Dec;54(16):4475-4484. (PMID: 39648662) Trials. 2022 Aug 15;23(1):658. (PMID: 35971137) Schizophr Res. 2011 Nov;132(2-3):125-30. (PMID: 21908175) Schizophr Res. 2012 Dec;142(1-3):96-8. (PMID: 23062750) Front Psychol. 2015 Oct 06;6:1450. (PMID: 26500570) Schizophr Bull. 2018 Jun 6;44(4):749-756. (PMID: 29040776) Schizophr Res. 2018 Dec;202:80-85. (PMID: 29954700) Schizophr Res. 2024 Jun;268:193-204. (PMID: 38493023) Lancet Psychiatry. 2018 Mar;5(3):217-226. (PMID: 29429948) Eur Psychiatry. 2021 Feb 18;64(1):e23. (PMID: 33597064) BMJ. 1998 Aug 1;317(7154):303-7. (PMID: 9685273) Schizophr Res. 2019 Sep;211:44-50. (PMID: 31326234) Schizophr Bull. 2011 Mar;37(2):300-5. (PMID: 20558531) Psychol Med. 2024 Nov;54(15):4173-4181. (PMID: 39552390) JMIR Serious Games. 2025 Dec 1;13:e77920. (PMID: 41328520) Schizophr Bull. 2010 Jan;36(1):192-204. (PMID: 18617485) BMJ Ment Health. 2023 Nov;26(1):. (PMID: 37945313) Br J Psychiatry. 2024 May;224(5):147-149. (PMID: 38652062) Psychiatry Res. 2014 May 15;216(2):198-205. (PMID: 24602992) Trials. 2019 Jan 11;20(1):43. (PMID: 30635021) Lancet Psychiatry. 2022 Jun;9(6):458-476. (PMID: 35523211) Psychol Med. 2021 Jan;51(2):244-253. (PMID: 31744588) Lancet Psychiatry. 2021 May;8(5):387-404. (PMID: 33862018) Lancet Psychiatry. 2016 Jul;3(7):685-92. (PMID: 27371990) Psychol Med. 2009 Jun;39(6):881-7. (PMID: 18845010) Lancet Psychiatry. 2022 May;9(5):375-388. (PMID: 35395204) JMIR Ment Health. 2022 Feb 18;9(2):e28502. (PMID: 35179501) Schizophr Res. 2017 May;183:22-30. (PMID: 27889383) Psychol Assess. 2019 Feb;31(2):139-158. (PMID: 30234319) Psychol Med. 2008 Jan;38(1):101-11. (PMID: 17903336) Br J Psychiatry Suppl. 1993 Dec;(22):39-44. (PMID: 8110442) Healthcare (Basel). 2021 Oct 23;9(11):. (PMID: 34828476) Behav Cogn Psychother. 2024 May;52(3):277-287. (PMID: 37942541) Behav Res Ther. 1998 Apr;36(4):455-70. (PMID: 9670605) Annu Rev Clin Psychol. 2005;1:577-606. (PMID: 17716100) Nat Med. 2025 Oct;31(10):3425-3439. (PMID: 40804323) Schizophr Bull. 2025 May 8;51(3):637-645. (PMID: 39847500) J Clin Psychol. 2018 Nov;74(11):1924-1937. (PMID: 30091140) Clin Psychol Rev. 2020 Jun;78:101854. (PMID: 32361339) Lancet Psychiatry. 2021 Aug;8(8):696-707. (PMID: 34246324) Neuroscience. 2017 Mar 14;345:203-217. (PMID: 27282085) Schizophr Bull. 2014 Nov;40(6):1338-46. (PMID: 24743864) Eur Arch Psychiatry Clin Neurosci. 2015 Mar;265(2):107-16. (PMID: 25261210) Int J Ment Health Syst. 2023 Mar 31;17(1):8. (PMID: 37004066) Lancet Child Adolesc Health. 2024 Jan;8(1):28-39. (PMID: 37980918) Schizophr Bull. 2024 Mar 7;50(2):233-235. (PMID: 38309718) Br J Psychiatry. 1997 Nov;171:420-6. (PMID: 9463599) J Clin Epidemiol. 2001 Apr;54(4):343-9. (PMID: 11297884) Br J Psychiatry. 1993 Apr;162:524-32. (PMID: 8481745) Br J Psychiatry. 2016 Jul;209(1):23-8. (PMID: 27198483) BMC Med Res Methodol. 2017 Dec 21;17(1):173. (PMID: 29268721) BMJ Ment Health. 2025 Nov 12;28(1):. (PMID: 41224483) Health Technol Assess. 2025 Nov;29(53):1-115. (PMID: 41217072) Acta Psychiatr Scand. 2000 Apr;101(4):323-9. (PMID: 10782554) Front Psychiatry. 2020 Jun 02;11:406. (PMID: 32581856) Lancet. 2019 Sep 14;394(10202):939-951. (PMID: 31303314) Br J Psychiatry. 2016 Jul;209(1):62-7. (PMID: 27151071) Front Psychol. 2015 Mar 27;6:323. (PMID: 25870572) Schizophr Res. 2019 Jan;203:66-79. (PMID: 29352708) Schizophrenia (Heidelb). 2025 Mar 6;11(1):38. (PMID: 40050627) Behav Cogn Psychother. 2019 Mar;47(2):230-243. (PMID: 30012233) Psychol Med. 2001 Oct;31(7):1293-306. (PMID: 11681555) Clin Psychol Rev. 2025 Nov;121:102644. (PMID: 40876312) Lancet Psychiatry. 2022 Mar;9(3):232-242. (PMID: 35183280) Schizophr Bull. 2018 Jun 6;44(4):737-748. (PMID: 28981848) Soc Psychiatry Psychiatr Epidemiol. 2016 Jul;51(7):921-36. (PMID: 27262562) Schizophr Bull. 2009 Jan;35(1):5-8. (PMID: 19074497) Nat Rev Dis Primers. 2025 Nov 27;11(1):83. (PMID: 41309720)
Grant Information:	148727 TrygFonden; 0134-00066B Danmarks Frie Forskningsfond; L-2021-00244 Fonden til Lægevidenskabens Fremme
Contributed Indexing:	Keywords: cognitive behavioral therapy; delusions; effect modifier; immersive virtual reality; paranoia; psychosis; schizophrenia spectrum disorders
Molecular Sequence:	ClinicalTrials.gov NCT04902066
Entry Date(s):	Date Created: 20260427 Date Completed: 20260715 Latest Revision: 20260902
Update Code:	20260903
PubMed Central ID:	PMC13125928
DOI:	10.1017/S0033291726103870
PMID:	42037481
Βάση Δεδομένων:	MEDLINE

Full Text Finder

Περιγραφή
ISSN:	1469-8978
DOI:	10.1017/S0033291726103870